Quantcast

Latest Critical Therapeutics Inc. Stories

2010-03-04 06:00:00

CARY, N.C., March 4 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX) today reported financial results for the three and 12 months ended December 31, 2009. Highlights Annual net revenues exceeded $100 million for the first time in Company history Fourth quarter net revenues increased $10.0 million, or 48%, to $30.8 million, compared to the fourth quarter of 2008 Non-GAAP income from operations(1) for the fourth quarter of $7.4 million based on GAAP income...

2009-11-04 06:00:00

CARY, N.C., Nov. 4 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported financial results for the three and nine months ended September 30, 2009. Recent Highlights Third quarter net revenues increased $2.5 million to $23.1 million, or 12%, compared to the third quarter of 2008 Non-GAAP income...

2009-08-11 06:00:00

CARY, N.C., Aug. 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported financial results for the three and six months ended June 30, 2009. Recent Highlights: Second quarter net revenues increase $10.9 million to $25.0 million, or 78%, compared to 2008 Cash balance improves to $15.5 million at...

2009-07-20 07:00:00

CARY, N.C., July 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets, announced today that David Price, Executive Vice President, Finance, and Chief Financial Officer, has been named Triangle Business Journal's CFO of the Year in the Small Public Business category. Award recipients were recognized at the inaugural...

2009-05-07 06:00:00

CARY, N.C., May 7 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today reported financial results for the first quarter ended March 31, 2009. Highlights: First quarter 2009 Net Revenues increased $21.3 million to $30.7 Million, or 225% Income from Operations increased $9.0 million to $10.4 Million, or 658% Net...

2009-03-26 06:00:00

CARY, N.C., March 26 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today reported financial results for the year ended December 31, 2008. Highlights: Full-Year 2008 Net Revenues more than doubled to $64.9 Million, an increase of 131% Income from Operations increased to $10.6 Million, and Cash Flow from Operations...

2008-12-11 07:00:00

CARY, N.C., Dec. 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today provided an update on the status of its integration activities following the closing of the business combination of Critical Therapeutics, Inc. and Cornerstone BioPharma Holdings, Inc. on October 31, 2008, and the renaming of the combined company as Cornerstone...

2008-10-20 18:00:30

Critical Therapeutics, Inc. (NASDAQ: CRTX), a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2008. Financial Results for the Three Months Ended September 30, 2008 and 2007 Total revenue for the third quarter of 2008 was $6.0 million, compared with $3.2 million in the third quarter of 2007. Total revenue for the third quarter...

2008-08-11 18:00:58

Critical Therapeutics, Inc. (NASDAQ: CRTX), a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2008. Financial Results for the Three Months Ended June 30, 2008 and 2007 Total revenue for the second quarter of 2008 was $3.9 million, compared with $3.4 million in the second quarter of 2007. Total revenue for the second quarter of 2007...

2007-10-08 09:00:09

Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that the Company has commercially launched Perforomist™ (formoterol fumarate) Inhalation Solution (Perforomist) with its marketing partner, Dey, L.P. (DEY), a subsidiary of Mylan Inc. (NYSE: MYL). Perforomist™ Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD)....


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related